Early results show COVID-19 pill by Chinese company can greatly lower hospitalization risk and death

A Chinese drugmaker is reporting positive test results for its COVID-19 pill. Early data from trials in Brazil appear promising, while more information is expected in the coming month. Suzhou-based Kintor Pharma started to develop the drug shortly after the initial outbreak last year. Proxalutamide is the only small-molecule oral drug treatment for COVID-19 inpatients which has entered phase III multiregional clinical trials.

Search Trends